Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Fang, Mu, Chenglin, Kwok, Hang Fai, Xu, Jiyuan, Wu, Yingliang, Liu, Wanhong, Sabatier, Jean-Marc, Annweiler, Cédric, Li, Xugang, Cao, Zhijian, Xie, Yingqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241724/
https://www.ncbi.nlm.nih.gov/pubmed/34239361
http://dx.doi.org/10.7150/ijbs.57810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241724/
https://www.ncbi.nlm.nih.gov/pubmed/34239361
http://dx.doi.org/10.7150/ijbs.57810

Ejemplares similares